Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 March 2014Website:
http://www.neurogene.comNext earnings report:
18 March 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 27 min agoDividend
Analysts recommendations
Institutional Ownership
NGNE Latest News
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neurogene Inc. ("Neurogene Inc.") (NASDAQ:NGNE) concerning possible violations of federal securities laws. Neurogene issued a press release on November 11, 2024, reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome.
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates. “The recently announced interim data from participants dosed with 1E15 vg in the NGN-401 clinical trial showed consistent improvements across multiple domains that define Rett syndrome, in contrast to what i.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who.
NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
NEW YORK CITY, NY / ACCESSWIRE / November 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Bad news on Monday caused the pharmaceutical company's shares to drop massively in after-hours trading, and they continued to slide through Tuesday. So, what was it that sent shares of Neurogene, a stock that was up 269% year-to-date, plummeting?
NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neurogene Inc. ("Neurogene Inc.") (NASDAQ:NGNE) concerning possible violations of federal securities laws. Neurogene issued a press release on November 11, 2024, reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome.
On Monday, Neurogene Inc. NGNE released interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial of NGN-401 gene therapy for female pediatric patients with Rett syndrome, a rare genetic neurological and developmental disorder.
What type of business is Neurogene?
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
What sector is Neurogene in?
Neurogene is in the Healthcare sector
What industry is Neurogene in?
Neurogene is in the Biotechnology industry
What country is Neurogene from?
Neurogene is headquartered in United States
When did Neurogene go public?
Neurogene initial public offering (IPO) was on 07 March 2014
What is Neurogene website?
https://www.neurogene.com
Is Neurogene in the S&P 500?
No, Neurogene is not included in the S&P 500 index
Is Neurogene in the NASDAQ 100?
No, Neurogene is not included in the NASDAQ 100 index
Is Neurogene in the Dow Jones?
No, Neurogene is not included in the Dow Jones index
When was Neurogene the previous earnings report?
No data
When does Neurogene earnings report?
The next expected earnings date for Neurogene is 18 March 2025